The purpose of the study was to highlight the most studied risk factors associated with the development and/or progression of diabetic nephropathy, with an emphasis on some important aspects that should be kept in mind by the physician. Materials and methods. Research materials are publications of national and foreign authors. The methods used were: system approach and system theoretical retrospective analysis of selected materials; generalization; medical and statistical method. Results and discussion. Timely diagnostics of diabetic nephropathy and elimination of risk factors of its development and progression are emphasized to be a difficult task of clinics of internal diseases particularly in conditions when amount of these risk factors is constantly growing. The most investigated risk factors associated with development and progression of diabetic nephropathy such as age, arterial hypertension, disorders of carbohydrate and lipid exchange, proteinuria are discussed in the article. Some peculiarities of correction of metabolic risk factors such as hyperglycemia and dyslipidemia as well as hemodynamic risk factors such as arterial hypertension and intraglomerular hypertension participated in development and progression of diabetic nephropathy are discussed with consideration of acting recommendations. Some aged and gender peculiarities of change of glomerular filtration rate as well as a role of arterial hypertension in progression of diabetic nephropathy through albuminuria are considered. A significance of glycosylated hemoglobin level as an independent risk factors of microalbuminuria is demonstrated. A role of secondary lipid exchange disorders due to type 2 diabetes mellitus in reduction of glomerular filtration rate and elevation of albumin/creatinine ratio as well as albuminuria presence is emphasized. A necessity of urinal detection of nephrin and podocin levels for an early diagnostics of diabetic nephropathy and monitoring of renal glomerular dysfunction in diabetes mellitus is discussed. Some risk factors related to appearance of albuminuria as well as association of albuminuria and proteinuria with glomerular and tubular structural changes in kidney are considered. A clinical significance of albumin/creatinine ratio calculation as an alternative to daily urinal protein concentration measuring for diabetic nephropathy screening is emphasized. Some risk factors related to close positive correlation with this ratio are considered. A role of genetic factors in the development of diabetic nephropathy with a participation of known today some genes candidates and a necessity of genealogical anamnesis definition to reveal a patient’s susceptibility to development of diabetic nephropathy is discussed. Conclusion. The contemporary recommendations for control of glycemia, correction of dyslipidemia and arterial hypertension which allow significantly reduce a risk of kidney impairment in diabetes mellitus or inhibit a progression of diabetic nephropathy in patients with albuminuria and proteinuria are given. A significance of detailed investigation of principles of development and progression of diabetic nephropathy for collaboration of effective diagnostic, treatment and preventive measures is emphasized

Keywords: diabetic nephropathy, risk factors of its development and progression

Full text: PDF (Ukr) 270K

1. Elhefnawy KA, Elsayed AM. Prevalence of diabetic kidney disease in patients with type 2diabetes mellitus. Egypt J Intern Med. 2019;31(2):149-154. https://doi.org/10.4103/ejim.ejim_113_18
2. KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Nephrol Dialys. 2021;23(2):9-121. https://doi.org/10.28996/2618-9801-2021-2suppl-9-121
3. Eftekhari A, Vahed SZ, Kavetskyy T, Rameshrad M, Jafari S, Chodari L, et al. Cell junction proteins: crossing the glomerular filtration barrier in diabetic nephropathy. Int J Biol Macromol. 2020 Apr 1;148:475-482. PMID: 31962072. https://doi.org/10.1016/j.ijbiomac.2020.01.168
4. Selby NM, Taal MW. An updated overview of diabetic nephropathy: Diagnosis, prognosis, treatment goals and latest guidelines. Diabetes Obes Metab. 2020 Apr;22 Suppl 1:3-15. PMID: 32267079. https://doi.org/10.1111/dom.14007
5. Zhang XX, Kong J, Yun K. Prevalence of diabetic nephropathy among patients with type 2 diabetes mellitus in China: a meta-analysis of observational studies. J Diabetes Res. 2020 Feb 3;2020:2315607. PMID: 32090116. PMCID: PMC7023800. https://doi.org/10.1155/2020/2315607
6. Shahwan MJ, Gacem SA, Zaidi SK. Prevalence of diabetic nephropathy and associated risk factors among type 2 diabetes mellitus patients in Ramallah, Palestine. Diabetes Metab Syndr. 2019 Mar-Apr;13(2):1491-1496. PMID: 31336511. https://doi.org/10.1016/j.dsx.2019.02.017
7. Russo GT, De Cosmo S, Viazzi F, Mirijello A, Ceriello A, Guida P, et al. Diabetic kidney disease in the elderly: prevalence and clinical correlates. BMC Geriatr. 2018 Feb 2;18(1):38. PMID: 29394888. PMCID: PMC5797340. https://doi.org/10.1186/s12877-018-0732-4
8. Maestroni S, Zerbini G. Diabetic Nephropathy – Research. In: Microvascular Disease in Diabetes. Tecilazich F, Ed. Wiley-Blackwell; 2020. p. 97-109. https://doi.org/10.1002/9781119309642.ch8
9. Khoury CC, Chen S, Ziyadeh FN. Pathophysiology of Diabetic Nephropathy. In: Chronic Renal Disease. Kimmel PL, Mark E. Rosenberg ME, Eds. Academic Press; 2020. p. 279-296. https://doi.org/10.1016/B978-0-12-815876-0.00019-X
10. Ormazabal V, Nair S, Elfeky O, Aguayo C, Salomon C, Zuñiga FA. Association between insulin resistance and the development of cardiovascular disease. Cardiovasc Diabetol. 2018 Aug 31;17(1):122. PMID: 30170598. PMCID: PMC6119242.
11. https://doi.org/10.1186/s12933-018-0762-4
12. Fu H, Liu S, Bastacky SI, Wang X, Tian XJ, Zhou D. Diabetic kidney disease revisited: a new perspective for a new era. Mol Metab. 2019 Dec;30:250-263. PMID: 31767176. PMCID: PMC6838932. https://doi.org/10.1016/j.molmet.2019.10.005
13. Smyth LJ, Cañadas-Garre M, Cappa RC, Maxwell AP, McKnight AJ. Genetic associations between genes in the renin-angiotensin-aldosterone system and renal disease: a systematic review and meta-analysis. BMJ Open. 2019 May 1;9(4):e026777. PMID: 31048445. PMCID: PMC6501980. https://doi.org/10.1136/bmjopen-2018-026777
14. Vodošek Hojs N, Bevc S, Ekart R, Hojs R. Oxidative stress markers in chronic kidney disease with emphasis on diabetic nephropathy. Antioxidants (Basel). 2020 Sep 27;9(10):925. PMID: 32992565. PMCID: PMC7600946. https://doi.org/10.3390/antiox9100925
15. Bhaisare SD, Rao AK, Jog AS, Kolapkar HU. Clinical study of urine albumin creatinine ratio as an earlier predictor of diabetic nephropathy. J Evolution Med Dental Sci. 2020;9(9):598-603. https://doi.org/10.14260/jemds/2020/133
16. Zaman SB, Karim MA, Hossain N, Al Kibria GM, Islam SMS. Plasma triglycerides as a risk factor for chronic kidney disease in type 2 diabetes mellitus: evidence from northeastern Thailand. Diabetes Res Clin Pract. 2018 Apr;138:238-245. PMID: 29448006. https://doi.org/10.1016/j.diabres.2018.02.011
17. Aliviameita P, Aliviameita A. Relationship between renal function test serum and lipid profile in patients with diabetes mellitus. WMA Mathcomtech. 2018;1114:012011. https://doi.org/10.1088/1742-6596/1114/1/012011
18. You A, Li Y, Tomlinson B, Yue L, Zhao K, Fan H, et al. Association between renal dysfunction and low HDL cholesterol among the elderly in China. Front Cardiovasc Med. 2021 May 12;8:644208. PMID: 34055931. PMCID: PMC8149893. https://doi.org/10.3389/fcvm.2021.644208
19. Bulbul MC, Dagel T, Afsar B, Ulusu NN, Kuwabara M, Covic A, et al. Disorders of lipid metabolism in chronic kidney disease. Blood Purif. 2018;46(2):144-152. PMID: 29705798. https://doi.org/10.1159/000488816
20. Barton M, Tharaux PL. Endothelin and the podocyte. In-depth review. Clin Kidney J. 2012;5:17-27. PMID: 26069741. PMCID: PMC4400467. https://doi.org/10.1093/ckj/sfs001
21. Rayego-Mateos S, Morgado-Pascual JL, Opazo-Ríos L, Guerrero-Hue M, García-Caballero C, Vázquez-Carballo C, et al. Pathogenetic pathways and therapeutic approaches targeting inflammation in diabetic nephropathy. Int J Mol Sci. 2020 May 27;21(11):3798. PMID: 32471207. PMCID: PMC7312633. https://doi.org/10.3390/ijms21113798
22. Goldfine AB, Shoelson SE. Therapeutic approaches targeting inflammation for diabetes and associated cardiovascular risk. J Clin Invest. 2017;127(1):83-93. PMID: 28045401. PMCID: PMC5199685. https://doi.org/10.1172/JCI88884
23. Kittiskulnam P, Thokanit NS, Katavetin P, Susanthitaphong P, Srisawat N, Praditpornsilpa K, et al. The magnitude of obesity and metabolic syndrome among diabetic chronic kidney disease population: A nationwide study. PLoS One. 2018 May 9;13(5):e0196332. PMID: 29742114. PMCID: PMC5942778. https://doi.org/10.1371/journal.pone.0196332
24. Jitraknatee J, Ruengorn C, Nochaiwong S. Prevalence and risk factors of chronic kidney disease among type 2 diabetes patients: a cross-sectional study in primary care practice. Sci Rep. 2020 Apr 10;10(1):6205. PMID: 32277150. PMCID: PMC7148316. https://doi.org/10.1038/s41598-020-63443-4
25. Chen YN, Wang PW, Tung SC, Kuo MC, Weng SW, Chou CK, et al. Association between Pro12Ala polymorphism and albuminuria in type 2 diabetic nephropathy. J Diabetes Investig. 2020 Jul;11(4):923-929. PMID: 31912623. PMCID: PMC7378428. https://doi.org/10.1111/jdi.13208
26. Afifa K, Belguith Asma S, Nabil H, Ahlem B, Mounira S, Kawthar Y, et al. Screening for nephropathy in diabetes mellitus: is a micral-test valid among all diabetics? Int J Chronic Dis. 2016;2016:2910627. PMID: 27294192. PMCID: PMC4887651. https://doi.org/10.1155/2016/2910627
27. Wei L, Xiao Y, Li L, Xiong X, Han Y, Zhu X, et al. The susceptibility genes in diabetic nephropathy. Kidney Dis (Basel). 2018 Nov;4(4):226-237. PMID: 30574499. PMCID: PMC6276750. https://doi.org/10.1159/000492633
28. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. ESC Scientific Document Group. 2019 ESC/EAS Guidelines for the management of dyslipidemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41:111-188. PMID: 31504418. https://doi.org/10.1093/eurheartj/ehz455